174 related articles for article (PubMed ID: 34670872)
1. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
[TBL] [Abstract][Full Text] [Related]
2. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
3. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
4. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
5. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
6.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Wang P; Zeng Z; Shen X; Tian X; Ye Q
DNA Cell Biol; 2020 Apr; 39(4):615-630. PubMed ID: 32105510
[TBL] [Abstract][Full Text] [Related]
8. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
9. A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.
Gao L; Xie ZC; Pang JS; Li TT; Chen G
Aging (Albany NY); 2019 Jan; 11(1):263-283. PubMed ID: 30640723
[TBL] [Abstract][Full Text] [Related]
10. Development of a 4-miRNA prognostic signature for endometrial cancer.
Huang J; Du F; Wang N
Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
[TBL] [Abstract][Full Text] [Related]
11. Gene Signatures and Prognostic Value of m6A RNA Methylation Regulators in Uterine Corpus Endometrial Carcinoma.
Feng Y; Yao C; Shen J; Zhou J
Discov Med; 2021; 31(164):111-120. PubMed ID: 35188885
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
13. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
14. A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Zeng Z; Cheng J; Ye Q; Zhang Y; Shen X; Cai J; Li M
DNA Cell Biol; 2020 Jun; 39(6):975-991. PubMed ID: 32397815
[TBL] [Abstract][Full Text] [Related]
15. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
16. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
17. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
18. A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
Wang Y; Xu M; Yang Q
Curr Probl Cancer; 2019 Apr; 43(2):167-176. PubMed ID: 29567372
[TBL] [Abstract][Full Text] [Related]
19. PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.
Wang X; Fang A; Peng Y; Yu J; Yu C; Xie J; Zheng Y; Song L; Li P; Li J; Kang X; Lin Y; Li W
J Cell Mol Med; 2023 Mar; 27(5):609-621. PubMed ID: 36756714
[TBL] [Abstract][Full Text] [Related]
20. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
